Table 4.
| Citation | Vehicle type | Material | NSAID | Delivery time frame | Treating | |
|---|---|---|---|---|---|---|
| Localized delivery | 31 | Hydrogel | PCLA-PEG-PCLA | Celecoxib | 100 days (in vitro), 4–8 weeks (in vivo) | Osteoarthritis |
| Localized delivery | 32 | Microparticles | PLGA | Celecoxib | 60 days | Diabetes in eye |
| Localized delivery | 33 | Nanostructure membrane | poly(N-methacryloyl glycine)/Bacterial nanocellulose | Diclofenac | 4 h | Dermal and oral delivery |
| Localized delivery | 34 | Film | PP | Diclofenac, Ibuprofen | ∼h, 1 day | Graft modification |
| Localized delivery | 35 | Film | PLGA | Ibuprofen | 10 days | |
| Localized delivery | 36 | Fibrous membrane | PLGA | Ibuprofen | 70 days | Tissue anti-adhesion barrier |
| Localized delivery | 37 | Microspheres | PLGA/PVA/Gelatin | Ibuprofen | 63 days | Osteoarthritis |
| Localized delivery | 38 | Microtubes | Polycaprolactone (PCL) | Ibuprofen | 30 days | Peripheral nerve regeneration (nerve guidance conduits) |
| Localized delivery | 39 | Hydrogel | Anionic nanofibrillar cellulose | Ketoprofen | > 72 h | |
| Localized delivery | 40 | Microparticles | PHB/chitosan | Ketoprofen | 2.5 days | |
| Localized delivery | 41 | Electrospun nanofibers | PLA | Ketoprofen | 12.5 days | |
| Localized delivery | 42 | Membrane | Polyurethane matrix | Ketoprofen | 2 h | |
| Localized delivery | 43 | Electrospun fibers/films | Chitosan/PVA/HA | Meloxicam | 1 day | Periodontal disease |
| Localized delivery | 44 | Electrospun nanofibers | PCL | Naproxen | ||
| Localized delivery | 45 | Microspheres | Polyorganophosphazene | Naproxen | 33 days 8 h | Periodontal disease |
| Localized Delivery | 46 | Electrospun fiber mat | Chitosan/HA/PVA | Piroxicam | 5 h | Periodontal disease |
NSAID: non-steroidal anti-inflammatory drug.